Skip to main content
HUM
NYSE Finance

Humana Reports Q1 Profit Decline Amid Rising Costs and Ongoing Regulatory Challenges

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$237.87
Mkt Cap
$28.557B
52W Low
$163.11
52W High
$315.348
Market data snapshot near publication time

summarizeSummary

Humana reported a decline in Q1 GAAP net income and EPS despite strong revenue and membership growth, while facing significant legal and regulatory challenges, including an appeal on the critical Medicare Advantage risk adjustment rule.


check_boxKey Events

  • Q1 Profitability Decline

    Net income attributable to Humana decreased by 4.7% to $1.19 billion, and diluted EPS fell by 4.6% to $9.83, compared to the prior year, despite a 23.5% increase in total revenues to $39.65 billion.

  • Rising Benefit Ratio

    The consolidated benefit ratio increased by 240 basis points to 89.4%, primarily due to the BY 2026 Star Ratings revenue headwind and higher benefit ratios from new individual Medicare Advantage members.

  • Significant Regulatory & Legal Risks

    The government is appealing a district court decision that vacated the Final RADV Rule, which could have a material adverse effect on Medicare Advantage payments. The company also faces ongoing DOJ information requests and multiple class-action lawsuits related to its Medicare Advantage business.

  • Strategic Acquisition

    Acquired MaxHealth, a Florida-based primary care organization, for approximately $908 million in cash, expanding its CenterWell segment.


auto_awesomeAnalysis

Humana's first-quarter results reveal a significant decline in GAAP net income and diluted EPS, primarily driven by a higher benefit ratio and charges from value creation initiatives, despite robust revenue and Medicare membership growth. The company faces substantial and ongoing legal and regulatory risks, including an appeal by the government regarding the critical Medicare Advantage risk adjustment (RADV) rule, which could materially impact future financial performance. Additionally, ongoing DOJ investigations and multiple class-action lawsuits add to the operational and financial uncertainty. While the acquisition of MaxHealth and a new debt issuance bolster strategic growth and liquidity, the overall profitability trend and the complex legal landscape present considerable headwinds for investors.

At the time of this filing, HUM was trading at $237.87 on NYSE in the Finance sector, with a market capitalization of approximately $28.6B. The 52-week trading range was $163.11 to $315.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HUM - Latest Insights

HUM
Apr 29, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
HUM
Apr 29, 2026, 6:15 AM EDT
Source: Reuters
Importance Score:
8
HUM
Apr 29, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
HUM
Apr 29, 2026, 6:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
HUM
Apr 27, 2026, 8:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
HUM
Mar 09, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
HUM
Mar 06, 2026, 7:30 AM EST
Filing Type: DEF 14A
Importance Score:
7
HUM
Mar 05, 2026, 5:22 PM EST
Filing Type: FWP
Importance Score:
8
HUM
Mar 05, 2026, 8:38 AM EST
Filing Type: 424B5
Importance Score:
7
HUM
Feb 19, 2026, 2:26 PM EST
Filing Type: 10-K
Importance Score:
8